Isatuximab
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 384 publications
Review of the first on-body injector (obi) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myeloma.
Journal: Expert opinion on drug delivery
Published: April 13, 2026
A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM).
Journal: Expert opinion on biological therapy
Published: March 17, 2026
Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 06, 2026
Efficacy and Safety of Newly Diagnosed Multiple Myeloma Combination Therapies: A Systematic Review Integrating Network Meta-Analysis and Real-World Vigilance Study.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: December 03, 2025
Impact of 1q vulnerabilities in patients treated with anti-CD38 monoclonal antibodies.
Journal: Frontiers in oncology
Published: December 01, 2025
Isatuximab: surface strike, deep response in AL amyloidosis.
Journal: Blood
Published: November 20, 2025
Time and Resource Implications of Subcutaneous Daratumumab-Based versus Intravenous Isatuximab-Based Treatment Regimens for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible.
Journal: Oncology and therapy
Published: October 31, 2025
A rabbit anti-human CD38 antibody for eliminating daratumumab and isatuximab interference in immunohematology testing.
Journal: Frontiers in immunology
Published: October 16, 2025
Last Updated: 04/28/2026